Onglyza (saxagliptin) and Komiglize XR (saxagliptin with metaformin HCL extended release) are Type 2 diabetes drugs designed to help control blood sugar. A new FDA warning points to the potential for heart failure after using one of these medications. Onglyza and Kombiglyze XR, approved by the FDA in 2009 and 2010, respectively, have become popular Type 2 diabetes medications because they control blood sugar without causing weight gain as may other blood glucose regulation drugs do. This new FDA warning may cause many physicians and patients to re-examine the benefits of these particular diabetes medications versus the risk of heart failure. RxWatch has issued a safety alert for Onglyza and Kombiglyze XR and is offering a free, no-obligation, confidential lawsuit consultation for anyone, or the families of those, who have suffered from heart disease, heart failure or had a heart attack after taking one of these drugs.
Onglyza and Kombiglyze XR are manufactured by AstraZeneca, the British-Swedish pharmaceutical giant that had almost $25 billion in sales in 2015. Although the FDA Heart Failure Warning did not occur until April 2016, AstraZeneca has been aware of the link between saxagliptin and heart problems since 2013. Prior to the FDA Warning for increased risk of heart failure, it was projected that Onglyza's annual sales would reach $2.47 billion by 2018. Onglyza produced $768 million for AstraZeneca in 2015.
Onglyza and Kombiglyze XR are DPP-4 inhibitor drugs that are used with diet and exercise to regulate blood glucose levels for Type 2 diabetes by helping increase insulin levels after meals, which helps the body utilize blood glucose as energy, resulting in stable blood sugar levels.
The FDA Onglyza Heart Failure Warning was finally issued following the 2013 publication of "Saxagliptin and Cardiovascular Outcome in Patients with Type 2 Diabetes Mellitus" in the New England Journal of Medicine. This medical study reviewed the outcome of over 16,000 saxagliptin (Onglyza and Kombiglyze XR) users over 2 to 3 years. This study concluded that diabetics taking Onglyza and Kombiglyze XR were 1.27 times more likely to be hospitalized for heart failure than diabetics taking other medications, a 27% increase. Heart failure refers to the generalized condition in which the heart is not able to pump enough blood to supply the body. The first sign of heart failure may be a heart attack.
Two independent medical studies analyzed users of Onglyza and Kombiglyze XR, both large and controlled and both published in leading peer-reviewed journals, found that using these antibiotics can double the risk of developing an aortic aneurysm or aortic dissection. This was discovered to be the case for both current and past Onglyza and Kombiglyze XR users.
Onder Law, the law firm behind RxWatch that recently won the $72 million baby powder ovarian cancer verdict against Johnson & Johnson, is offering a free, no-obligation, confidential consultation to anyone who used Onglyza and Kombiglyze XR and was diagnosed with heart failure, heart disease or suffered a heart attack.
Onder Law will represent all persons involved in a Onglyza or Kombiglyze XR lawsuit on a contingency basis, meaning there are never any legal fees unless we win compensation in your case. For a free no-obligation consultation please complete the brief online contact form or call us at 1-800-799-2824 and one of our attorneys handling national* Onglyza and Kombiglyze XR lawsuits will contact you to answer any of your questions. Onglyza and Kombiglyze XR lawsuits are NOT class action lawsuits. Pharmaceutical lawsuits generally become Multi-District Litigations that are consolidated in the federal court system, but where plaintiffs receive compensation individually based upon the extent of the damage caused.
A leader in cancer research at Harvard University asserts that perhaps 10,000 cases of ovarian cancer can be blamed each year on perineal talc use in the US. Despite the existence of evidence that talc-based products are dangerous and can cause cancer, talc is not regulated in the US. The American Cancer Society estimates that in 2013, about 22,240 new cases of ovarian cancer will be diagnosed, while 14,030 women will die as a result of ovarian cancer in the US.
Roundup weed killer, manufactured by Monsanto, uses a chemical called glyphosate, which the World Health Organization labeled as a probable carcinogen in 2015. Roundup is the most popular of all glyphosate-based herbicides. As little as 8 hours of Roundup exposure has been linked to an increased risk of non-Hodgkin lymphoma, multiple myeloma, and leukemia. Millions of gardeners, landscapers, farmers and others have been exposed to Roundup cancer risks.
Physiomesh is a form of surgical mesh that has been used in hernia repair surgeries. Ethicon Physiomesh was used in ventral hernia repair and has been pulled from the market due to a high failure rate. Persons with Ethicon Physiomesh have experienced an array of complications that include pain, infection, hernia recurrence, adhesion or scar-tissue buildup, intestinal blockage, bleeding, perforation, organ damage, and the need for revision surgery.